Several thermo-sensitive TRP channels (TRPV1, -3; TRPA1) have been implicated in itch. In contrast, the role of transient receptor potential vanilloid type-4 (TRPV4) in itch is unknown. Therefore, we investigated if TRPV4, a temperature-sensitive cation channel, plays an important role in acute itch in mice. Four different pruritogens including serotonin (5-hydroxytrytamine, 5-HT), histamine, SLIGRL (PAR2/MrgprC11 agonist) and chloroquine (MrgprA3 agonist) were intradermally injected and itch-related scratching behavior was assessed. TRPV4 knockout (TRPV4KO) mice exhibited significantly fewer 5-HT-evoked scratching bouts compared to wildtype (WT) mice. Notably, no differences between TRPV4KO and WT mice were observed in the number of scratch bouts elicited by SLIGRL and histamine. Pretreatment with a TRPV4 antagonist significantly attenuated 5-HT-evoked scratching in vivo. Using calcium imaging in cultured primary murine dorsal root ganglion (DRG) neurons, the response of neurons after 5-HT application, but not other pruritogens, was significantly lower in TRPV4KO compared to WT mice. A TRPV4 antagonist significantly suppressed 5-HT-evoked responses in DRG cells from WT mice. Approximately 90% of 5-HT-sensitive DRG neurons were immunoreactive for an antibody to TRPV4, as assessed by calcium imaging. These results indicate that serotonin-induced itch is linked to TRPV4.
Introduction
Itch can be elicited by a wide variety of chemical stimuli, including inflammatory mediators: amines, cytokines, proteases, neuropeptides, and Mas-related G-protein-coupled receptor (Mrgpr) agonists (Akiyama and Carstens, 2014) . Histamine, an inflammatory mediator, is the best-known itch inducer and is predominantly released by mast cells and basophils, and possibly keratinocytes (Dvorak, 1998; Inami et al., 2013) . Histamine H1 and H4 receptors play a role in histamine-evoked itch (Bell et al., 2004) . Serotonin (5-HT), another inflammatory mediator, is released by mast cells, melanocytes, and platelets, to evoke itch (Kushnir-Sukhov et al., 2007; Slominski et al., 2003; Turetta et al., 2004) . While the intradermal injection of 5-HT elicits robust scratching behaviors in rodents (Nojima and Carstens, 2003; Yamaguchi et al., 1999) , either the intradermal injection or the iontophoretic application of 5-HT elicits mild to moderate itch in humans (Hosogi et al., 2006; Weisshaar et al., 2004; Weisshaar et al., 1997) . Proteases like trypsins, kallikreins or tryptase exert pruritogenic effects through the activation of protease-activated receptors (PARs). PAR-2 is overexpressed in the skin of atopic dermatitis patients and its tethered ligand, SLIGRL, evokes itch-related behaviors in mice (Akiyama et al., 2009; Steinhoff et al., 2003) . Mrgprs have recently been linked to chemically-evoked itch (Han et al., 2013) . Chloroquine, an agonist of MrgprA3, as well as bovine adrenal medullary peptide BAM8-22, an agonist of MrgprC11, both elicit itch. It has been reported that SLIGRL, a tethered ligand for PAR-2, in addition acts as an agonist of MrgprC11 (Liu et al., 2011) .
Transient receptor potential (TRP) ion channels are involved in sensory physiology including itch and pain as well as vision, taste, olfaction, hearing, touch, and thermosensation. Recent studies have revealed that several thermo-sensitive TRP channels are implicated in itch (Akiyama and Carstens, 2013) . TRPV1 is activated by noxious heat (≥ 43 °C) and is required for itch evoked by histamine and IL-31 (Cevikbas et al., 2014; Imamachi et al., 2009) . Rodent TRPA1 has been reported to respond to cold temperatures (below 17-18°C) (Chen et al., 2013a) and is required for itch evoked by chloroquine, IL-31, thymic stromal lymphopoietin, endothelin-1, and bile acids (Cevikbas et al., 2014; KidoNakahara et al., 2014; Lieu et al., 2014; Wilson et al., 2011; Wilson et al., 2013) . TRPV3 is activated by warm temperatures (range 33-39 °C). Mice harboring a gain-of-function mutation in TRPV3 developed dermatitis accompanied by itch behavior (Yoshioka et al., 2009) . TRPV4 is another TRP channel activated by moderately warm temperatures (range 27-34 °C) and is expressed in sensory neurons as well as keratinocytes in the skin. TRPV4 mRNA was upregulated in skin with itching burn scars (Yang et al., 2015) and in photodermatitis (Moore et al., 2013) . However, the role of TRPV4 in itch is largely unknown. We tested if TRPV4 is required for certain types of itch in mice and demonstrate that TRPV4 is required for the transmission of serotonin-induced itch, but not of three other tested pruritogens.
evoked scratching was significantly enhanced in TRPV4KO mice (Fig. 1a) . In the present study, we did not further investigate the mechanisms underlying this enhancement. 5-HTelicited scratching in TRPA1KO and TRPV1KO mice was not significantly different compared to that in WT mice (Fig. 1a) . In the cheek model, 5-HT predominantly elicited scratching which was significantly diminished in TRPV4KO mice (Fig. 1b) . These findings suggest that 5-HT-elicted scratching requires TRPV4 in vivo.
To confirm the role of TRPV4 in 5-HT-evoked itch, a pharmacological approach was also used. The TRPV4 antagonist HC067047 significantly inhibited 5-HT-evoked scratching (Fig. 2) . 5-HT-evoked scratching was not significantly affected by pretreatment with the H1 histamine receptor antagonist terfenadine, but was significantly inhibited by pretreatment with the 5-HT2 antagonist, ketanserin (Fig. 2) . These results are consistent with previous reports (Akiyama et al., 2012; Yamaguchi et al., 1999) .
Calcium imaging
To investigate whether 5-HT-responsive cells express TRPV4, calcium imaging of DRG cells were performed, followed by immunostaining. The specificity of the TRPV4 antibody was confirmed by detecting immunoreactivity of TRPV4 in DRG cells of WT mice (Fig.  3b ), but not TRPV4KO mice (Fig. 3c, n=129 ). To investigate whether 5-HT-responsive cells express TRPV4, calcium imaging of DRG cells were performed, followed by immunostaining. Eighteen percent (206/1131) of all DRG cells from WT mice were immunopositive for the TRPV4 antibody. Of those DRG cells shown by calcium imaging to respond to 5-HT, 93% (15/16) were immunopositive for TRPV4 (Fig. 3a) . Eighty one percent of TRPV4-immunoreactive DRG cells were unresponsive to 5-HT.
We compared 5-HT-evoked responses in DRG neurons isolated from TRPV1KO, TRPA1KO, and TRPV4KO mice with those isolated from WT mice. DRG cells isolated from TRPV4KO mice showed a significant decrease in the proportion that were 5-HTsensitive (2/112). In contrast, there were no significant differences in the proportions of 5-HT-sensitive DRG neurons isolated from TRPA1KO mice (26/423) and TRPV1KO (9/205) compared with those from WT mice (10/202, Fig. 4 ). DRG cells isolated from TRPV4KO mice showed no changes in the proportions of histamine-, chloroquine-or SLIGRL-sensitive neurons compared to those from WT mice (Fig. 4) .
A pharmacological approach was again taken to confirm whether TRPV4 functions downstream of 5-HT receptor activation in DRG neurons. Responses of DRG neurons to 5-HT were markedly reduced by application of the TRPV4 antagonist (Fig. 5a) . Fig. 5b also shows that the TRPV4 antagonist significantly reduced the mean 5-HT-evoked responses. In contrast, controls showed no decline in successive 5-HT-evoked responses (Fig. 5c ). The majority of 5-HT-sensitive DRG neurons responded to capsaicin (TRPV1 agonist), hypotonic solution (TRPV4 activator) and mustard oil (TRPA1 agonist) ( Fig. 5d ), while ≤30% of 5-HT-sensitive DRG cells responded to eugenol or carvacrol, agonists of TRPV3/ TRPA1. The majority of histamine-sensitive DRG neurons responded to capsaicin (Fig. 5e ), while the majority of chloroquine-sensitive DRG neurons responded to mustard oil (Fig. 5f ). The majority of SLIGRL-sensitive DRG neurons responded to both capsaicin and mustard oil (Fig. 5g ).
Discussion
Chronic itch is the most frequent symptom in dermatology with a significant impact on patients' quality of life. Defining the mediators, receptors, circuits of receptor interactions and signaling pathways involved in histamine-independent itch may lead to novel therapies for this unmet medical need in dermatological therapy. In contrast to TRPV1, TRPV3 and TRPA1, the role of TRPV4 in the regulation of itch is currently unknown. Our findings support the hypothesis that TRPV4 mediates itch evoked by 5-HT, but not by histamine, chloroquine or the PAR2/MrgprA3 agonist SLIGRL. This conclusion is supported by the following: (1) 5-HT-evoked scratching was suppressed in mice genetically lacking TRPV4 as well as mice treated with a TRPV4 antagonist. (2) Calcium imaging studies of DRG neurons provided confirming results. (3) Over 90% of 5-HT-sensitive DRG cells expressed TRPV4. Given that 5-HT is upregulated in lesional skin of atopic dermatitis, psoriasis and contact dermatitis (El-Nour et al., 2007; Huang et al., 2004a, b; Nordlind et al., 2008) , TRPV4 antagonists may be useful in treating chronic itch associated with these skin conditions.
Additionally, we demonstrate that TRPV4KO mice did not exhibit any reduction in scratching evoked by chloroquine, histamine, or SLIGRL. It was previously reported that histamine-evoked scratching is mediated by TRPV1 and that chloroquine-and SLIGRLevoked scratching requires TRPA1 (Imamachi et al., 2009; Liu et al., 2011; Wilson et al., 2011) . TRPV1 is not required for 5-HT-evoked scratching (Imamachi et al., 2009) , consistent with our present data. TRPA1 is required for scratching evoked by a 5-HT 7 agonist, but not a 5-HT 2 agonist Morita et al., 2015) . Although we did not observe a reduction of 5-HT-evoked scratching in TRPA1KO mice, TRPA1 might be involved in 5-HT-evoked itch. A previous study showed that several TRP channels modulate itch signaling evoked by chloroquine (Than et al., 2013) . Itch evoked by 5-HT could be modulated by several TRP channels, including TRPV4 and TRPA1.
TRPV4 expression has been demonstrated in DRG and trigeminal ganglion (TG) neurons, and in cutaneous nerves (Chen et al., 2013b; Girard et al., 2013; Gopinath et al., 2005; Suzuki et al., 2003; Vergnolle et al., 2010; Wang et al., 2015; Yamada et al., 2009) . While large DRG and TG neurons express TRPV4 (Chen et al., 2013b; Suzuki et al., 2003) , small DRG and TG (peptidergic) neurons expressing calcitonin gene related peptide (CGRP) and/or substance P (SP) also express TRPV4 (Chen et al., 2013b; Moore et al., 2013; Vergnolle et al., 2010) . In the present study, we found that the majority of 5-HT-sensitive DRG neurons express TRPV4. Although there is currently no direct evidence that any type of serotonin receptor is coupled with TRPV4, it was reported that a 5-HT-induced Ca 2+ response is mediated by TRPV4 in pulmonary arterial smooth muscle cells (Xia et al., 2013) . 5-HT 2A and 5-HT 1B receptor subtypes are presumably involved in this response (Rodat-Despoix et al., 2008) . In mouse DRG neurons, 5-HT sensitized neuronal responses to 4αPDD, a selective TRPV4 agonist, through phospholipase C and protein kinase Cdependent pathways . These findings imply that certain serotonin receptors are coupled with TRPV4.
The present findings confirm that 5-HT-evoked itch is histamine-independent (Akiyama et al., 2012; Imamachi et al., 2009) . DRG neurons express 5-HT 1B , 5-HT 1D , 5-HT 1F , 5-HT 2A , 5-HT 3 , 5-HT 4 , 5-HT 5B and 5-HT 7 receptor subtypes (Ohta et al., 2006) . The 5-HT receptor subtypes involved in itch are currently under investigation. We presently observed that the 5-HT 2 antagonist ketanserin abolished 5-HT-evoked scratching, consistent with a previous study (Yamaguchi et al., 1999) . A recent study reported that a 5-HT 3 antagonist inhibited 5-HT-evoked scratching in mice (Ostadhadi et al., 2015) . However, previous studies showed that 5-HT 3 antagonists failed to inhibit 5-HT-evoked scratching in mice and rats, and itch in humans (Nojima and Carstens, 2003; Weisshaar et al., 1997; Yamaguchi et al., 1999) , suggesting that 5-HT 3 is less likely involved in 5-HT-evoked itch. A very recent study suggests that 5-HT 7 is involved in 5-HT-evoked itch (Morita et al., 2015) . There is no report regarding the effects of the 5-HT 2 antagonist or the 5-HT 7 antagonist on 5-HT-evoked itch in humans.
TRPV4 is largely expressed in skin epidermal keratinocytes and plays a role in epidermal barrier homeostasis (Kida et al., 2012) , inflammation and photodermatitis-associated pain (Moore et al., 2013) . Keratinocytes also express 5-HT 1A , 5-HT 1B , 5-HT 2A , 5-HT 2B , and 5-HT 7 receptor subtypes (Slominski et al., 2003) , suggesting that 5-HT may be able to activate keratinocytes in conjunction with TRPV4. A recent study also reported that 5-HT stimulates IL-6 release from primary human keratinocytes (Kaneko et al., 2009) . It is thus possible that 5-HT could activate one or more 5-HT subtypes coupled with TRPV4, as noted above, to evoke release of substances from keratinocytes that could act on anatomically closely associated sensory nerve endings. A recent study revealed that activation of TRPV4 in keratinocytes contributes to release of endothelin-1 (ET-1), another important pruitogen (Moore et al., 2013) . However, ET-1 is unlikely to be involved in 5-HT-evoked itch, as ET-1-evoked itch is mediated by TRPA1, but not TRPV4 (Kido-Nakahara et al., 2014).
In summary, we demonstrate that TRPV4 is involved in histamine-independent itch associated with serotonin, and is thus linked to activation of one or more 5-HT receptor subtypes. In contrast, TRPV4 is not linked to other pruritogen receptors for histamine, chloroquine or PAR2/MrgprA3 agonists. Further studies are demanded to fully explore to which pruritic pathways TRPV4 is linked. Furthermore, it will be significant to clarify the role of TRPV4 in pruritic diseases in humans.
Materials and Methods

Behavioral tests
Experiments were performed using adult male knockout mice lacking TRPV4 (TRPV4KO) (Grant et al., 2007; Liedtke et al., 2003) , TRPV1 (TRPV1KO), TRPA1 (TRPA1KO), and wild-type (WT; littermates of TRPV4KO mice; C57BL/6 mice) (19-34 g) under a protocol approved by the UC Davis Animal Care and Use Committee. Knockout mice were maintained under specific pathogen-free conditions and were bred by backcrossing with C57BL/6 mice. The fur on the rostral back or the cheek was shaved and mice were habituated to the Plexiglas recording arena one week prior to testing. For intraperitoneal (ip) injections, either terfenadine (30 mg/kg; Sigma-Aldrich, St. Louis, MO) (Akiyama et al., 2012) , ketanserin (3 mg/kg; Sigma-Aldrich) (Yamaguchi et al., 1999) , HC067047 (10 mg/kg; Tocris Bioscience) (Everaerts et al., 2010) , or vehicle (10%DMSO+10%Tween80 in saline) was administered, followed 30 min later by intradermal (id) injection (10 μl) of either chloroquine (193 nmol; Sigma-Aldrich), histamine (271 nmol; Sigma-Aldrich), serotonin (47 nmol; Sigma-Aldrich), or SLIGRL (76 nmol; Quality Controlled Biochemicals, Hopkinton, MA). Microinjections were made id in the nape of the neck or cheek using a 30 G needle attached to a Hamilton microsyringe by PE-50 tubing. Immediately after the id injection, mice were placed into the arena and videotaped from above for 30 min. Generally 3-4 mice were injected and videotaped simultaneously. Immediately after commencing videotaping, all investigators left the room. Videotapes were reviewed by investigators blinded to the treatment, and the number of scratch bouts was counted at 5-min intervals. A scratch bout was defined as one or more rapid back-and-forth hind paw motion(s) directed toward and contacting the injection site, and ending with licking or biting of the toes and/or placement of the hind paw on the floor. Hind paw movements directed away from the injection site (e.g., ear-scratching) and grooming movements were not counted. A wipe was defined as a singular motion of the ipsilateral, but not bilateral, forelimb beginning at the caudal extent of the injected cheek, and proceeding in a rostral direction. The inner aspect of the ankle and/or forelimb typically contacted the cheek with the paw closed. One-way ANOVA followed by the Bonferroni post-test or unpaired t-tests (two-tailed) was used to compare the total number of scratch bouts across pretreatment groups. In all cases p<0.05 was considered to be significant.
Calcium imaging
Experiments were performed using adult male TRPV4KO mice, TRPA1KO mice, TRPV1KO mice, and WT (C57BL/6) mice (18-34 g) under a protocol approved by the UC Davis Animal Care and Use Committee. The animal was euthanized under sodium pentobarbital anesthesia, and upper-to mid-cervical DRGs were acutely dissected and enzymatically digested at 37°C for 10 min in HBSS (Invitrogen, Carlsbad, CA) containing 20 U/ml papain (Worthington Biochemical, Lakewood, NJ) and 6.7 mg/ml L-cysteine (Sigma, St. Louis, MO), followed by 10 min at 37°C in HBSS containing 3 mg/ml collagenase (Worthington Biochemical). The ganglia were then mechanically triturated using fire-polished glass pipettes. DRG cells were pelleted; suspended in MEM with Earle's balanced salt solution (Gibco, Life Technologies, Carlsbad, CA) containing 100 U/ml penicillin, 100 μg/ml streptomycin (Gibco, Life Technologies), 1× vitamin (Gibco, Life Technologies), and 10% horse serum (Quad Five, Ryegate, MT); plated on poly-d-lysinecoated glass coverslips; and cultured for 16-24 h. DRG cells were incubated in Ringer's solution (pH 7.4, 140 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 4.54 mM NaOH) with 10 μM Fura-2 AM and 0.05% of Pluronic F-127 (Invitrogen). Coverslips were mounted on a custom-made aluminum perfusion block and viewed through an inverted microscope (Nikon TS100, Technical Instruments, Burlingame, CA). Fluorescence was excited by UV light at 340 nm and 380 nm alternately, and emitted light was collected via a CoolSNAP camera attached to a Lambda LS lamp and a Lambda optical filter changer (Sutter Instrument, Novato, CA). Ratiometric measurements were made using Simple PCI software (Hamamatsu, Sewickley, PA) every 3 s.
Solutions were delivered by a solenoid-controlled eight-channel perfusion system (ValveLink, AutoMate Scientific, San Francisco, CA). One of the following agents was delivered: chloroquine (300 μM), histamine (100 μM), 5-HT (100 μM) and the PAR-2/ MrgprA3 agonist SLIGRL-NH2 (100 μM). In some experiments, one of the following agents was delivered after the delivery of prutiogen: capsaicin (1 μM), eugenol (100 μM), carvacrol (100 μM), 30% hypotonic solution, and mustard oil (100 μM). Stimulus duration was 30 s (10 s for capsaicin). In other experiments, 5-HT was delivered three times at 3.5-min intervals. HC067047 (1 μM) (Everaerts et al., 2010) was delivered beginning 10 s prior to the second 5-HT application for a duration of 2 min. Potassium chloride (144 mM) was always delivered at the end of each experiment. Ratios were normalized to baseline. Cells were judged to be sensitive if the ratio value increased by >10% of the resting level following chemical application. Only cells responsive to high potassium were included for analysis. After the experiment, coverslips were etched with a diamond pen to provide landmarks for alignment with subsequent immunohistofluoresent labeling of the same cells. Fisher's exact test was used to compare the percentages of pruritogen-sensitive cells between groups.
Immunocytochemistry
After calcium imaging, DRG cells in the culture dish were fixed in formalin, followed by 30% sucrose, and then incubated with 5% normal serum. They were immunostained with rabbit anti-TRPV4 antibody (1:300; Abcam, Cambridge MA) at 4°C overnight, followed by incubation with the corresponding secondary antibody conjugated with Alexa Fluor 488 (1:500; Life Technologies, Grand Island, NY) for 2 h. DRG cells were counterstained with DAPI in the mounting medium (Vector Laboratories, Burlingame, CA). Images were captured using a fluorescence microscope (Nikon Eclipse Ti; Technical Instruments). Immunohistofluorescent images were aligned with images captured during calcium imaging to determine the percentages of 5-HT-responsive DRG cells that were double labeled for TRPV4. 
